$ACAD

6 stories mentioning ACADUpdated 1h ago

Every FINWIRES story that references ACAD, newest first.

Acadia Pharmaceuticals to Gain From Daybue, Nuplazid Growth; RADIANT Data Adds Risk, Morgan Stanley Says

Acadia Pharmaceuticals (ACAD) could benefit from wider Daybue use, steady Nuplazid growth, higher cash flow and a strong balance sheet, but upcoming Remlifanserin trial data and the stock's valuation keep the outlook balanced, Morgan Stanley said in a note emailed Monday.STIX should help bring more patients to Daybue rather than mainly shift users away from the oral version, supporting further growth in the Rett syndrome business, Morgan Stanley said, adding that the firm expects Nuplazid to remain a steady growth driver and stay on track toward about $1 billion in sales.The upcoming phase 2 RADIANT results for Remlifanserin will be a major factor for the stock, with efficacy, safety, responder, cognitive and motor data helping investors judge the drug's potential, according to the note.The investment firm said it expects Acadia's financial position to improve as sales rise, estimating operating margin will increase to 15% in 2028 from 9% in 2026, while free cash flow could grow to $280 million from $131 million and Acadia's net-cash position should give the company room to fund growth and manage its drug pipeline.Morgan Stanley kept its equal-weight rating and $27 price target, saying stronger business performance is balanced by the stock trading above its target and the risk around the upcoming RADIANT results.Price: $29.53, Change: $+0.32, Percent Change: +1.10%

$ACAD

Wire5d ago

ACADIA Pharmaceuticals' Q2 Daybue Sales Beat on Stix Formulation Uptake Supports Improved Outlook, RBC Says

ACADIA Pharmaceuticals' (ACAD) Daybue sales beat in Q2 due to the Stix formulation uptake on a better tolerability profile support an improved outlook, while Nuplazid to treat hallucinations linked with Parkinson's disease continues to perform solidly, RBC Capital Markets said in a research report emailed Wednesday.An expected European Union launch in Q4 in Germany, followed by other countries, and with 60% of June US scripts being for Stix, could support 2026 sales of up to $500 million, according to the note.The company's Remlifanserin to treat hallucinations related to Alzheimer's disease is now the near-term focal point, with trial enrolment complete and readout window narrowing, analysts wrote.The brokerage said it reiterated its outperform rating on the stock and boosted its price target to $37 per share from $36.Price: $28.69, Change: $+1.54, Percent Change: +5.67%

$ACAD

Sectors45d ago

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks were higher late Friday afternoon, with the NYSE Healthcare Index rising 2.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.5%.The iShares Biotechnology ETF (IBB) climbed 1%.In corporate news, Eli Lilly (LLY) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for Jaypirca to treat adults with chronic lymphocytic leukemia across all lines of therapy. Lilly shares popped 7%.Johnson & Johnson (JNJ) shares gained 4% after the company said Friday that a European Medicines Agency committee recommended expanding Tecvayli's approval in combination with daratumumab for adults with relapsed or refractory multiple myeloma who have received at least one prior therapy.Cumberland Pharmaceuticals (CPIX) shares jumped past 9% after the company presented updated phase 2 results showing additional evidence that ifetroban may help protect heart function in patients with Duchenne muscular dystrophy.Acadia Pharmaceuticals (ACAD) shares climbed nearly 8% after it said the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion of Daybu following a re-examination procedure, recommending approval of the drug to treat neurobehavioral symptoms of Rett syndrome in patients aged five and older.

$ACAD$CPIX$JNJ$LLY

Sectors45d ago

Sector Update: Healthcare Stocks Gain Friday Afternoon

Healthcare stocks were higher Friday afternoon, with the NYSE Healthcare Index rising 2.3% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.5%.The iShares Biotechnology ETF (IBB) climbed 1.5%.In corporate news, Johnson & Johnson (JNJ) shares gained 3.5% after the company said Friday that a European Medicines Agency committee recommended expanding Tecvayli's approval in combination with daratumumab for adults with relapsed or refractory multiple myeloma who have received at least one prior therapy.Cumberland Pharmaceuticals (CPIX) shares jumped past 7% after the company presented updated phase 2 results showing additional evidence that ifetroban may help protect heart function in patients with Duchenne muscular dystrophy.Acadia Pharmaceuticals (ACAD) shares climbed nearly 9% after it said the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion of Daybu following a re-examination procedure, recommending approval of the drug to treat neurobehavioral symptoms of Rett syndrome in patients aged five and older.

$ACAD$CPIX$JNJ

Sectors45d ago

Sector Update: Healthcare Stocks Mixed Premarket Friday

Healthcare stocks were mixed premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) marginally higher and the iShares Biotechnology ETF (IBB) down 0.1%.ACADIA Pharmaceuticals (ACAD) stock was up nearly 10% after the company said the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion of Daybu following a re-examination procedure, recommending approval of the drug to treat neurobehavioral symptoms of Rett syndrome in patients aged five and older.Incyte (INCY) shares were up 1.8% after the company said the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of Opzelura cream for adults with moderate atopic dermatitis.Avalo Therapeutics (AVTX) will be added to the small-cap Russell 2000 index and the broad-market Russell 3000 index, effective after market close Friday. Shares of Avalo Therapeutics were up more than 1% pre-bell.

$ACAD$AVTX$IBB$INCY$XLV

Sectors45d ago

Sector Update: Healthcare

Healthcare stocks were narrowly mixed premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) marginally higher and the iShares Biotechnology ETF (IBB) down 0.1%.Acadia Pharmaceuticals (ACAD) was up more than 13% after the company said the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion of Daybu following a re-examination procedure, recommending approval of the drug to treat neurobehavioral symptoms of Rett syndrome in patients aged five and older.

$ACAD

Track with the FINWIRES app suite

FolioX

Track ACAD in your portfolio

WheelAI

Analyze ACAD options with the wheel strategy

StockInsider

See market sentiment on ACAD